| Title: |
SAMHD1 expression contributes to doxorubicin resistance and predicts survival outcomes in diffuse large B-cell lymphoma patients |
| Authors: |
Daddacha, Waaqo; Monroe, Dominique; Schlafstein, Ashley J; Withers, Allison E; Thompson, Elizabeth B; Danelia, Diana; Luong, Nho C; Sesay, Fatmata; Rath, Sandip K; Usoro, Edidiong R; Essien, Mark E; Jung, Andrew T; Jiang, Jinmeng G; Hu, Jiaxuan; Mahboubi, Bijan; Williams, Arilyn; Steinbeck, Julia E; Yang, Xiaofeng; Buchwald, Zachary S; Dynan, William S; Switchenko, Jeffrey M; Kim, Baek; Khan, Mohammad K; Jaye, David L; Yu, David S |
| Contributors: |
NIH; NCI; NIAID |
| Source: |
NAR Cancer ; volume 6, issue 1 ; ISSN 2632-8674 |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2024 |
| Description: |
Diffuse large B-cell lymphoma (DLBCL) is a commonly diagnosed, aggressive non-Hodgkin's lymphoma. While R-CHOP chemoimmunotherapy is potentially curative, about 40% of DLBCL patients will fail, highlighting the need to identify biomarkers to optimize management. SAMHD1 has a dNTPase-independent role in promoting resection to facilitate DNA double-strand break (DSB) repair by homologous recombination. We evaluated the relationship of SAMHD1 levels with sensitivity to DSB-sensitizing agents in DLBCL cells and the association of SAMHD1 expression with clinical outcomes in 79 DLBCL patients treated with definitive therapy and an independent cohort dataset of 234 DLBCL patients. Low SAMHD1 expression, Vpx-mediated, or siRNA-mediated degradation/depletion in DLBCL cells was associated with greater sensitivity to doxorubicin and PARP inhibitors. On Kaplan–Meier log-rank survival analysis, low SAMHD1 expression was associated with improved overall survival (OS), which on subset analysis remained significant only in patients with advanced stage (III-IV) and moderate to high risk (2–5 International Prognostic Index (IPI)). The association of low SAMHD1 expression with improved OS remained significant on multivariate analysis independent of other adverse factors, including IPI, and was validated in an independent cohort. Our findings suggest that SAMHD1 expression mediates doxorubicin resistance and may be an important prognostic biomarker in advanced, higher-risk DLBCL patients. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/narcan/zcae007 |
| Availability: |
https://doi.org/10.1093/narcan/zcae007; https://academic.oup.com/narcancer/article-pdf/6/1/zcae007/56753955/zcae007.pdf |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.76F5D0A3 |
| Database: |
BASE |